-
Je něco špatně v tomto záznamu ?
Mass Spectrometric Analysis of Exhaled Breath for the Identification of Volatile Organic Compound Biomarkers in Esophageal and Gastric Adenocarcinoma
S. Kumar, J. Huang, N. Abbassi-Ghadi, HA. Mackenzie, KA. Veselkov, JM. Hoare, LB. Lovat, P. Španěl, D. Smith, GB. Hanna,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem
- MeSH
- adenokarcinom diagnóza metabolismus MeSH
- dechové testy MeSH
- hmotnostní spektrometrie * MeSH
- hodnocení rizik MeSH
- lidé středního věku MeSH
- lidé MeSH
- metody pro podporu rozhodování MeSH
- nádorové biomarkery metabolismus MeSH
- nádory jícnu diagnóza metabolismus MeSH
- nádory žaludku diagnóza metabolismus MeSH
- ROC křivka MeSH
- senioři MeSH
- studie případů a kontrol MeSH
- těkavé organické sloučeniny metabolismus MeSH
- vydechnutí MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- práce podpořená grantem MeSH
OBJECTIVE: The present study assessed whether exhaled breath analysis using Selected Ion Flow Tube Mass Spectrometry could distinguish esophageal and gastric adenocarcinoma from noncancer controls. BACKGROUND: The majority of patients with upper gastrointestinal cancer present with advanced disease, resulting in poor long-term survival rates. Novel methods are needed to diagnose potentially curable upper gastrointestinal malignancies. METHODS: A Profile-3 Selected Ion Flow Tube Mass Spectrometry instrument was used for analysis of volatile organic compounds (VOCs) within exhaled breath samples. All study participants had undergone upper gastrointestinal endoscopy on the day of breath sampling. Receiver operating characteristic analysis and a diagnostic risk prediction model were used to assess the discriminatory accuracy of the identified VOCs. RESULTS: Exhaled breath samples were analyzed from 81 patients with esophageal (N = 48) or gastric adenocarcinoma (N = 33) and 129 controls including Barrett's metaplasia (N = 16), benign upper gastrointestinal diseases (N = 62), or a normal upper gastrointestinal tract (N = 51). Twelve VOCs-pentanoic acid, hexanoic acid, phenol, methyl phenol, ethyl phenol, butanal, pentanal, hexanal, heptanal, octanal, nonanal, and decanal-were present at significantly higher concentrations (P < 0.05) in the cancer groups than in the noncancer controls. The area under the ROC curve using these significant VOCs to discriminate esophageal and gastric adenocarcinoma from those with normal upper gastrointestinal tracts was 0.97 and 0.98, respectively. The area under the ROC curve for the model and validation subsets of the diagnostic prediction model was 0.92 ± 0.01 and 0.87 ± 0.03, respectively. CONCLUSIONS: Distinct exhaled breath VOC profiles can distinguish patients with esophageal and gastric adenocarcinoma from noncancer controls.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010634
- 003
- CZ-PrNML
- 005
- 20160412104525.0
- 007
- ta
- 008
- 160408s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/SLA.0000000000001101 $2 doi
- 024 7_
- $a 10.1097/SLA.0000000000001101 $2 doi
- 035 __
- $a (PubMed)25575255
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kumar, Sacheen $u *Department of Surgery and Cancer, Imperial College London, St Mary's Hospital, London, UK †Department of Medicine, Imperial College London, St Mary's Hospital, London, UK ‡Department of Surgery and Interventional Science, National Medical Laser Centre, University College London, London, UK §J. Heyrovsky Institute of Physical Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic ¶Institute for Science and Technology in Medicine, Keele University, Guy Hilton Research Centre, Hartshill, UK.
- 245 10
- $a Mass Spectrometric Analysis of Exhaled Breath for the Identification of Volatile Organic Compound Biomarkers in Esophageal and Gastric Adenocarcinoma / $c S. Kumar, J. Huang, N. Abbassi-Ghadi, HA. Mackenzie, KA. Veselkov, JM. Hoare, LB. Lovat, P. Španěl, D. Smith, GB. Hanna,
- 520 9_
- $a OBJECTIVE: The present study assessed whether exhaled breath analysis using Selected Ion Flow Tube Mass Spectrometry could distinguish esophageal and gastric adenocarcinoma from noncancer controls. BACKGROUND: The majority of patients with upper gastrointestinal cancer present with advanced disease, resulting in poor long-term survival rates. Novel methods are needed to diagnose potentially curable upper gastrointestinal malignancies. METHODS: A Profile-3 Selected Ion Flow Tube Mass Spectrometry instrument was used for analysis of volatile organic compounds (VOCs) within exhaled breath samples. All study participants had undergone upper gastrointestinal endoscopy on the day of breath sampling. Receiver operating characteristic analysis and a diagnostic risk prediction model were used to assess the discriminatory accuracy of the identified VOCs. RESULTS: Exhaled breath samples were analyzed from 81 patients with esophageal (N = 48) or gastric adenocarcinoma (N = 33) and 129 controls including Barrett's metaplasia (N = 16), benign upper gastrointestinal diseases (N = 62), or a normal upper gastrointestinal tract (N = 51). Twelve VOCs-pentanoic acid, hexanoic acid, phenol, methyl phenol, ethyl phenol, butanal, pentanal, hexanal, heptanal, octanal, nonanal, and decanal-were present at significantly higher concentrations (P < 0.05) in the cancer groups than in the noncancer controls. The area under the ROC curve using these significant VOCs to discriminate esophageal and gastric adenocarcinoma from those with normal upper gastrointestinal tracts was 0.97 and 0.98, respectively. The area under the ROC curve for the model and validation subsets of the diagnostic prediction model was 0.92 ± 0.01 and 0.87 ± 0.03, respectively. CONCLUSIONS: Distinct exhaled breath VOC profiles can distinguish patients with esophageal and gastric adenocarcinoma from noncancer controls.
- 650 _2
- $a adenokarcinom $x diagnóza $x metabolismus $7 D000230
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a nádorové biomarkery $x metabolismus $7 D014408
- 650 _2
- $a dechové testy $7 D001944
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a metody pro podporu rozhodování $7 D003661
- 650 _2
- $a nádory jícnu $x diagnóza $x metabolismus $7 D004938
- 650 _2
- $a vydechnutí $7 D045853
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a hmotnostní spektrometrie $7 D013058
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a ROC křivka $7 D012372
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a nádory žaludku $x diagnóza $x metabolismus $7 D013274
- 650 _2
- $a těkavé organické sloučeniny $x metabolismus $7 D055549
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Huang, Juzheng
- 700 1_
- $a Abbassi-Ghadi, Nima $7 gn_A_00000226
- 700 1_
- $a Mackenzie, Hugh A
- 700 1_
- $a Veselkov, Kirill A
- 700 1_
- $a Hoare, Jonathan M
- 700 1_
- $a Lovat, Laurence B
- 700 1_
- $a Španěl, Patrik
- 700 1_
- $a Smith, David
- 700 1_
- $a Hanna, George B
- 773 0_
- $w MED00009202 $t Annals of surgery $x 1528-1140 $g Roč. 262, č. 6 (2015), s. 981-90
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25575255 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20160412104609 $b ABA008
- 999 __
- $a ok $b bmc $g 1114063 $s 935002
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 262 $c 6 $d 981-90 $i 1528-1140 $m Annals of surgery $n Ann Surg $x MED00009202
- LZP __
- $a Pubmed-20160408